Conclusions: More decrease in B cell count and more increase in BAFF level were observed in RA patients receiving non-biologic DMARDs. Conversely, APRIL levels were not affected by treatment. The contribution of B lymphocyte to RA pathogenesis goes beyond autoantibody production. Disturbances in B cell homeostasis in RA are not only due to disease process itself but closely related to the use of anti-rheumatic drugs. Background: High-density lipoproteins (HDL) are the plasma lipoproteins responsible for reverse cholesterol transport. Its protective effect on cardiovascular disease is attributed to the cholesterol efflux capacity as well as to its anti-oxidant and anti-inflammatory properties. HDL low levels are associated with immune diseases, including systemic lupus erythematosus and rheumatoid arthritis, implying a potential link between HDL and immunity. There is few evidence on the effects of HDL on human T cells. Animal studies suggested that HDL inhibits lymphocyte proliferation 1 , but the only study in humans showed that HDL from young and healthy subjects increases the proliferation of lymphocytes 2 . Previous studies also showed that HDL levels are positively correlated with the prevalence of regulator T cells in peripheral blood 3 . Furthermore, it has been shown that one of the main actions of HDL in lymphocytes is the disaggregation of lipid rafts provoked by cholesterol efflux from the membrane, but the final consequences of this effect are not known. Objectives: To determine the in vitro effects of HDL in human T cell proliferation and in the frequency of FoxP3+ regulator T cells. Methods: Peripheral blood mononuclear cells from six healthy donors were cultured with and without HDL to measure membrane cholesterol and proliferative response to CD3/CD28 stimulation. Membrane cholesterol was measured by filipin binding, assessed by flow cytometry. T cell proliferation was studied by Ki-67 expression and cell trace staining for multiple generations. T cell phenotyping and FoxP3 fluorescence were analyzed by flow cytometry. Results: HDL significantly reduced the amount of membrane cholesterol in CD4+ T cells, after 24 hours in culture. When added in the absence of stimulation, HDL did not induce any proliferation in CD4+ T cells. When added in conjunction with CD3/CD28 stimulation, HDL significantly increased the proliferation of CD4+ T cells. T cell phenotyping showed a significant increase in CD4+CD25+ FoxP3 fluorescence, after culture with HDL. Conclusions: This study shows that HDL promotes cholesterol efflux from the membrane of CD4+ T cells in vitro and increases CD4+ T cell proliferation. However, the increase in T cell numbers seem to favor the expression of FoxP3 in regulator in T cells, which is associated with suppression of inflammation. With the development of therapies to increase HDL levels, the knowledge of the HDL effects on T cell subsets is very important for the future management of cardiovascular and rheumatic diseases. Background: T follicular helper cells (Tfh) are necessary for B-cell maturation and differentiation in the germinal centers (GC). The signaling lymphocyte activation molecule family (SLAMF) receptors on the cell surface mediate T cell:B cell interaction for formation and maintenance of GC. But it remains to be elucidated whether SLAMF is expressed in circulating T follicular helper cells (cTfh). Objectives: The aim of this study was to investigate the levels of SLAMF3 and SLAMF6 on cTfh and to analyze their association with disease activity in systemic lupus erythematosus (SLE) patients. Methods: Blood samples were collected from 50 SLE patients, 24 Sjogren's syndrome (SS) patients and 25 age-and sex-matched healthy controls (HCs). In this study, CXCR5, programmed cell death protein 1 (PD-1), and CD4 were used as markers to define cTfh in peripheral blood mononuclear cells (PBMCs). The expression levels of SLMAF3 and SLMAF6 on cTfh were compared to that of circulating B cell subsets by flow cytometry. Clinical features including disease activity and laboratory tests were analyzed according to expression of SLAMF3 and SLAMF6. Results: Surface expression of SLAMF6 on CD4 T cells was significantly increased in SLE patients compared to SS patients (mean fluorescence intensity [MFI] , mean ± SD: 1291±319 vs 1098±147, p=0.015) and HCs (1291±319 vs 1094±243, p=0.011). But there was no difference in expression of SLAMF3 on CD4 T cells between SLE patients and SS patients or HCs. SLAMF6 expressions on cTfh cells, identified as CD4 + CXCR5 + PD-1 + , were significantly increased in SLE patients than in SS patients (1500±270 vs 1296±140, p=0.001) and HCs (1500±270 vs 1295±161, p=0.001). SLAMF6 expressions on cTfh cells had correlation with systemic lupus erythematosus disease activity index (SLEDAI) (Spearman's rho=0.477, p=0.001), proteinuria (rho=0.321, p=0.030) and double strand DNA (rho=0.340, p=0.026) in SLE patients. Moreover, expression levels of SLAMF6 on cTfh cells were correlated with those of several B cell subsets including total B cells (CD19 + ), naïve B cells (CD19 + CD27 -IgD + ) and class-
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